[Translation] A non-randomized, open-label, first-in-human international multicenter phase I/II clinical study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of CBP-1019 for injection in patients with advanced malignant solid tumors
1)Ⅰa期:
评估CBP-1019在晚期恶性肿瘤患者中的安全性和耐受性;
确定CBP-1019在晚期恶性肿瘤患者的最大耐受剂量(MTD)和Ⅱ期推荐剂量(RP2D);
2)Ⅰb/Ⅱ期:评估CBP-1019在晚期恶性肿瘤患者中的客观缓解率(ORR)。
[Translation] 1) Phase Ia:
To evaluate the safety and tolerability of CBP-1019 in patients with advanced malignancies;
Determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of CBP-1019 in patients with advanced malignant tumors;
2) Phase Ib/II: To evaluate the objective response rate (ORR) of CBP-1019 in patients with advanced malignant tumors.